Sirolimus causes relaxation of human vascular smooth muscle: A novel action of sirolimus mediated via ATP-sensitive potassium channels

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 3, 2007, Pages 1204-1208

  Ghatta, Srinivas ^a,c   Tunstall, Radhika R ^a   Kareem, Sohail ^b   Rahman, Mohamed ^b   O'Rourke, Stephen T ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 AMINOPYRIDINE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; APAMIN; APRIKALIM; CALCIUM ACTIVATED POTASSIUM CHANNEL; GLIBENCLAMIDE; IBERIOTOXIN; INDOMETACIN; PHENYLEPHRINE; RAPAMYCIN; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE RELAXATION; PRIORITY JOURNAL; RADIAL ARTERY; VASCULAR SMOOTH MUSCLE;

ADENOSINE TRIPHOSPHATE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ION CHANNEL GATING; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RADIAL ARTERY; SIROLIMUS; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 33847147689     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.115329     Document Type: Article

References (33)

1. Ashcroft SJ and Ashcroft FM (1990) Properties and functions of ATP-sensitive K-channels. Cell Signal 2:197-214.
2. Asnaghi L, Bruno P, Priulla M, and Nicolin A (2004) mTOR: a protein kinase switching between life and death. Pharmacol Res 50:545-549.
3. Atwal KS (1992) Modulation of potassium channels by organic molecules. Med Res Rev 12:569-591.
4. Banks BE, Brown C, Burgess GM, Burnstock G, Claret M, Cocks TM, and Jenkinson DH (1979) Apamin blocks certain neurotransmitter-induced increases in potassium permeability. Nature (Lond) 282:415-417.
5. Brayden JE (1996) Potassium channels in vascular smooth muscle. Clin Exp Pharmacol Physiol 23:1069-1076.
6. + channel opener cromakalim on the rabbit aorta: comparison with the calcium antagonist isradipine. Br J Pharmacol 95:741-752.
7. Corbin F, Blaise GA, Parent M, Chen H, and Daloze PM (1994) Effect of rapamycin on rat aortic ring vasomotion. J Cardiovasc Pharmacol 24:813-817.
8. (+) currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin. Am J Physiol 278:H886-H897.
9. Fattori R and Piva T (2003) Drug-eluting stents in vascular intervention. Lancet 361:247-249.
10. Galvez A, Gimenez-Gallego G, Reuben JP, Roy-Contancin L, Feigenbaum P, Kaczorowski GJ, and Garcia ML (1990) Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J Biol Chem 265:11083-11090.
11. Gardiner SM, March JE, Kemp PA, Fallgren B, and Bennett T (2004) Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. Br J Pharmacol 141:634-643.
12. Guarda E, Marchant E, Fajuri A, Martinez A, Moran S, Mendez M, Uriarte P, Valenzuela E, and Lazen R (2004) Oral rapamycin to prevent human coronary stent restenosis: a pilot study. Am Heart J 148:e9.
13. Hamilton TC, Weir SW, and Weston AH (1986) Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol 88:103-111.
14. Hiatt BL, Carter AJ, and Yeung AC (2001) The drug-eluting stent: is it the Holy Grail? Rev Cardiovasc Med 2:190-196.
15. Hille B (2001) Ion Channels of Excitable Membranes, Sinauer Assoc., Sunderland, MA.
16. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, and Serruys PW (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27:166-170.
17. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, and Perrault LP (2002) Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 21:990-998.
18. Marks AR (2003) Rapamycin: signaling in vascular smooth muscle. Transplant Proc 35:231S-233S.
19. Milliard S, Silva A, Blaise G, Chen H, Xu D, Qi S, and Daloze P (1998) Rapamycin's effect on vasomotion in the rat. Transplant Proc 30:1036-1038.
20. Miura H, Wachtel RE, Loberiza FR Jr, Saito T, Miura M, Nicolosi AC, and Gutterman DD (2003) Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. Circ Res 92:151-158.
21. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, et al. (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780.
22. O'Rourke ST (1996a) Effects of potassium channel blockers on resting tone in isolated coronary arteries. J Cardiovasc Pharmacol 27:636-642.
23. ATP channel activation mediates nicorandil-induced relaxation of nitrate-tolerant coronary arteries. J Cardiovasc Pharmacol 27:831-837.
24. O'Rourke ST, Vanhoutte PM, and Miller VM (2005) Biology of blood vessels: vascular pharmacology, in Vascular Medicine: A Companion to Braunwald's Heart Disease (Creager M, Dzau VJ, and Loscalzo J eds) pp 71-98, Saunders Elsevier, Philadelphia, PA.
25. Rodriguez AE, Rodriguez Alemparte M, Vigo CF, Fernandez Pereira C, Llaurado C, Vetcher D, Pocovi A, and Ambrose J (2005) Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Heart 91:1433-1437.
26. Schreiber SL (1991) Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science (Wash DC) 251:283-287.
27. Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35:7S-14S.
28. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, Centemero M, Maldonado G, Abizaid AS, Pinto I, et al. (2003) Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 107:24-27.
29. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, et al. (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-1193.
30. + channel is modulated by FK506 and rapamycin. Brain Res 786:255-258.
31. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, and Hess OM (2005) Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46:231-236.
32. Wareing M, Bai X, Seghier F, Turner CM, Greenwood SL, Baker PN, Taggart MJ, and Fyfe GK (2006) Expression and function of potassium channels in the human placental vasculature. Am J Physiol 291:R437-R446.
33. Yu MY, Gao RL, Jiang J, Cheng SJ, Yuan JQ, Wang CN, Zheng JG, Meng L, and Zi ZJ (2004) Pharmacokinetics of rapamycin-eluting stents in miniswine coronary model. Chin Med J (Engl) 117:1459-1463.